Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

(2013) Georgia Hatzivassiliou et al.   NATURE

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

(2013) David T W Jones et al.   NATURE GENETICS

Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas

(2013)   NATURE GENETICS

Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy

(2013) Thomas Botton et al.   Pigment Cell & Melanoma Research

Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas

(2013) A. J. Sievert et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report

(2012) B. C. Widemann et al.   CLINICAL CANCER RESEARCH

Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib

(2012) Carlo Spirli et al.   HEPATOLOGY

Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma

(2012) Eric Bouffet et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group

(2012) Joann L. Ater et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas

(2012) Eugene I. Hwang et al.   PEDIATRIC BLOOD & CANCER

Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas

(2012) AeRang Kim et al.   PEDIATRIC BLOOD & CANCER

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

(2011) David Capper et al.   ACTA NEUROPATHOLOGICA

An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice

(2011) Jan Gronych et al.   JOURNAL OF CLINICAL INVESTIGATION

BRAFAlterations in Primary Glial and Glioneuronal Neoplasms of the Central Nervous System With Identification of 2 Novel KIAA1549

(2011) Alex Lin et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging

(2011) Jianqiang Wu et al.   PEDIATRIC BLOOD & CANCER

Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma

(2010) Keith T. Flaherty et al.   CANCER BIOLOGY & THERAPY

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma

(2009) Andrey Korshunov et al.   ACTA NEUROPATHOLOGICA

Gliomas in patients with neurofibromatosis type 1

(2009) Anne C Albers et al.   Expert Review of Neurotherapeutics

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

(2009) N. T. Ihle et al.   MOLECULAR CANCER THERAPEUTICS

Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan

(2009) Roger J. Packer et al.   PEDIATRIC BLOOD & CANCER

Dermatologic symptoms associated with the multikinase inhibitor sorafenib

(2008) Caroline Robert et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY